INTRODUCTION
Nowadays, around 80-85% of children with acute lymphoblastic leukemia (ALL) can be definitively cured through the use of risk-oriented chemotherapy protocols (1) (2) (3) (4) . However, there are still subsets of children with ALL in whom the probability of event-free survival (EFS) with chemotherapy remains unsatisfactory, due to a high chance of disease recurrence.
Over the last years, much research on childhood ALL has focused on the validation of biologic and clinical prognostic variables able to identify patients at high risk (HR) of relapse. These characteristics predicting disease recurrence have varied over time.
Currently, some biological risk factors conveying a dismal prognosis in childhood ALL can be identified already at diagnosis. They include early thymocyte precursor phenotype, cytogenetic anomalies such as t(9;22), t(4;11), intrachromosomal amplification of chromosome 21 or molecular lesions recently identified as predicting biological resistance to conventional treatment (e.g. Ikaros mutations or JAK2 mutations) (5) (6) (7) (8) . Other prognostic factors, such as lack of achieving complete remission (CR) at the end of induction therapy, reflect sensitivity of leukemia cells to treatment (9) .
Additionally, in the last years, response to induction treatment, measured by evaluation of minimal residual disease (MRD), was shown to have an even stronger predictive value on the risk of leukemia recurrence (10, 11) .
Over the past decades, differences in definition of HR criteria and in frontline chemotherapy protocols among the childhood ALL cooperative groups have produced varying results, with a reported cure rate ranging from 30% to 60% (1) (2) (3) (4) (12) (13) (14) (15) .
The dynamic evolution of the results obtained with chemotherapy protocols has led to relevant modifications of the eligibility criteria for allogeneic hematopoietic stem cell transplantation (HSCT), so that, for instance, patients with B-cell precursor ALL and more than 100x10 9 /L white blood cells (WBC) at diagnosis not responding to the steroid prephase should not be offered transplantation. In this study, 357 children were enrolled, 280 of whom received chemotherapy and 77 chemotherapy followed by related-donor HSCT, on the basis of genetic chance (i.e., availability of an HLA-identical donor). The 5-year disease-free survival (DFS) was 40.6%
in children allocated to chemotherapy and 56.7% in those given HSCT (p=0.02). Balduzzi et al. concluded that children with HR ALL in CR1 benefit from related-donor HSCT compared with chemotherapy. The gap between the two strategies increases as the risk profile of the patient worsens. Indeed, children who were eligible for the study because of induction failure benefited more than others from related-donor availability (21).
Recently, Balduzzi et al. discussed, in the same cohort of patients they had previously analyzed, the impact of the time elapsed in CR1 on prognosis, as well as the potential influence of waiting time to transplantation. The relative advantage of HSCT from compatible related donors in HR childhood ALL was found whatever the time elapsed from CR1 to HSCT (22). 
Statistical analysis
The criteria used for defining CR, neutrophil and platelet engraftment, acute and chronic GvHD (aGvHD and cGvHD), transplantation-related mortality (TRM), relapse, overall survival (OS), and DFS are reported in the online supplement (36, 37).
OS and DFS were calculated according to the Kaplan-Meier method. Acute GvHD and cGvHD occurrence, TRM and relapse incidence (RI), were expressed as cumulative incidence curves, in order to adjust the analysis for competing risks. The significance of differences between the DFS curves was estimated by the log-rank test (Mantel-Cox), while, in univariate analyses, Gray's test was used to assess differences between RI and TRM (38). A multivariate analysis on DFS was performed using the Cox proportional regression model (39), while the proportional sub-distribution hazard regression model was used to perform RI and TRM multivariate analyses. P values <.05 were considered to be statistically significant. Further details on statistical analyses are shown in the online supplement.
RESULTS
The median follow-up was 6.8 years (range, 1.6-18.9) for surviving patients, and 0.9 years for deceased patients (range, 0.2-4.3). 
Engraftment and GvHD

Overall and Disease-Free Survival
The 10-year OS probability was 63.4% (95% CI, 57-70) (see also Figure 1 ).
The 10-year probability of DFS for all patients analyzed in the study was 61% (95% CI, 54-68) (Figure 1) . In univariate analyses, factors influencing DFS probability were patient age at diagnosis, and aGVHD severity (Supplementary Figure 3 A-C).
In univariate analyses, DFS was better in patients with grade 0-II aGvHD than in those with grade III-IV aGvHD (65% [95% CI, 58-62] and 40% [95% CI, 22-58], p=0.002).
Other variables had no impact on DFS (see also Supplementary table 1 for details).
In multivariate analyses, the occurrence of grade IV aGvHD (RR=3.8 [95% CI, 1.58-9.20], p=0.002) was an independent factor associated with worse DFS. On the contrary, the occurrence of grade I aGvHD (RR=0.54 [95% CI, 0.29-0.99], p=0.05) and an age at diagnosis between 1 and 9 years (p=0.045) were independent favorable prognostic variables for DFS (see also Table 3 for details).
Relapse Incidence
The median time from HSCT to relapse was 8 months (range 2-28). The overall RI was between diagnosis and HSCT and occurrence of grade II and IV aGvHD remained independent prognostic variables for RI (see also Table 3 ).
Transplantation-Related Mortality
The overall cumulative incidence of TRM was 15% (95% CI, 11-21) ( Figure 1) . In univariate analyses, factors significantly associated with an increased risk of TRM were age at diagnosis and transplantation, year of transplantation by donor type, stem cell (SC) source and occurrence of acute or chronic GvHD (Supplementary table 3 ).
In detail, TRM was lower for children aged 1-9 years at diagnosis as compared with those aged Patients with grade III and IV aGvHD had TRM of 32% (95% CI, 16-61) and 82% (95% CI, 62-100), respectively, versus 13% (95% CI, 7-25), 3% (95% CI, 1-14) and 12% (95% CI, 6-26) of patients with grade II, I and 0 aGvHD, respectively (p<0.00001) (Figure 2 C) .
None of the other analyzed variables were associated with an increased incidence of TRM (Supplementary table 3 
Minimal Residual Disease
Overall, among the patients who had been enrolled in the AIEOP-BFM ALL-2000 protocol, 100 had MRD results available at TP1 and TP2. On the basis of these results, 27 out of these 100 patients were classified as MRD-IR patients and 73 as MRD-HR patients. Similarly, the Children's Oncology Group reported a 5-year DFS of 58.6% in a small cohort of HR-ALL patients in CR1 who received HSCT from a family member (41). Noteworthy, the probability of DFS of our children with t(9;22) approached 60%, a figure comparable to that of Ph-negative ALL patients and to be considered remarkable having been mainly obtained in patients treated in an era before the introduction of tyrosine kinase inhibitors.
Our results indicate that after 1999 transplant outcomes are similar in recipients of UD and MFD. Specifically, there were no obvious differences in DFS, and most importantly, in the risk of TRM. These results are in agreement with previously published findings by the Italian pediatric group in children or adolescents with ALL in second CR (24, 42) and suggest that indications to HSCT in CR1 should be similar for patients with either a HLAidentical sibling or a matched UD.
We observed that the 10-14 year-old patient group had a worse 10-year DFS in comparison to 1-9 year-old patients (RR We also analyzed the impact of risk stratification based on MRD at day +33 and +78 from diagnosis on HSCT outcome. MRD has already proven to be the most sensitive method to evaluate treatment response and, thus, an important prognostic factor for a better stratification of patients in different risk classes in front-line treatment protocols (45, 46). A low-intensity GvHD prophylaxis has been reported to facilitate a better immune control of leukemia cells, this resulting into a decreased risk of relapse (49). The benefit offered by the occurrence of GvHD in terms of reduction of disease recurrence can, however, be offset by a higher incidence of TRM. In our cohort, considering patients who did not have aGvHD as the reference group, a lower relapse incidence was observed in patients who developed grade II or grade IV aGvHD, the latter having, however, a TRM of 82%. In multivariate analysis, a significantly better probability of DFS was found only in patients who developed grade I aGvHD, while grade II aGvHD was associated with a trend towards better DFS. Altogether, these data suggest that only GvHD of mild severity can favorably impact on final outcome.
We found an inverse correlation between the time elapsed from diagnosis to HSCT and the risk of relapse. Specifically, no relapse event was reported in patients who underwent HSCT beyond 12 months from diagnosis, while a higher RI was observed in those transplanted within 6 and/or 12 months from diagnosis. The most plausible explanation for this finding might be that patients who received HSCT beyond 12 months from diagnosis could have been already cured by chemotherapy. However, we cannot rule out that a longer chemotherapy consolidation might have had a positive impact on post-HSCT relapse risk.
The higher TRM observed in our patients given PB progenitors confirms previously published data by Eapen et al. (50). Thus, BM must be preferentially chosen over PB as SC source in children with either malignant or non-malignant disorders, although, for UD, the ultimate choice of the SC source pertains to the donor. In case the UD chooses to donate PBSC, the risk of performing transplantation has to be carefully evaluated.
In this study we demonstrated that a remarkable progress in terms of reduction of TRM has been achieved over the years, especially for transplants performed after 2000.
Specifically, we observed no death for bleeding complications in patients transplanted after 2000, reasonably attributable to the improvement of supportive care (see Supplementary   table 4 ).
In conclusion, our data indicate that allogeneic HSCT is a suitable option for a subgroup of ALL CR1 children with well-defined HR features. Since in the most recent period the outcome of MFD and UD recipients is comparable, nowadays, the indications for transplantation from either an HLA-identical sibling or an unrelated volunteer are to be considered identical. Overall, these indications significantly changed over time and are more restricted with respect to those adopted in the past years. 
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